Biomarkers in huntington's and Parkinson's disease

Annals of the New York Academy of Sciences

Volumn 1180, Issue , 2009, Pages 97-110

  O'Keeffe, Gráinne C ^a   Michell, Andrew W ^a   Barker, Roger A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

"wet" biomarker; Biomarker; Huntington's disease; Imaging; Motor measures; Parkinson's disease

Indexed keywords

6 FLUORODOPA F 18; 8 HYDROXYDEOXYGUANOSINE; ALPHA SYNUCLEIN; BIOLOGICAL MARKER; CARBOXYLYASE; DNA; GLUTATHIONE; HUNTINGTIN; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; LEVODOPA; RACLOPRIDE; TUMOR NECROSIS FACTOR ALPHA; URIC ACID;

CEREBROSPINAL FLUID; COGNITION; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE MARKER; DOPAMINERGIC NERVE CELL; DRUG EFFECT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC MANIPULATION; HUMAN; HUNTINGTON CHOREA; LEWY BODY; MOOD; MOTIVATION; MOTOR ACTIVITY; MOTOR CONTROL; NEUROCHEMISTRY; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARKINSON DISEASE; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; QUALITY OF LIFE; REPRODUCIBILITY; SACCADIC EYE MOVEMENT; SENSITIVITY AND SPECIFICITY; SUBSTANTIA NIGRA; URIC ACID BLOOD LEVEL;

BIOLOGICAL MARKERS; HUMANS; HUNTINGTON DISEASE; PARKINSON DISEASE; PHENOTYPE;

EID: 70449346196     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04943.x     Document Type: Conference Paper

References (33)

1. Hughes, A.J. et al. 1992. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinicopathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55: 181-184.
2. Williams-Gray, C.H. et al. 2007. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 130: 1787-1798.
3. 1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72: 971-983.
4. Wright, B.L. & R.A. Barker. 2007. Established and emerging therapies for Huntington's disease. Curr. Mol. Med. 7: 579-587.
5. Noth, J., K. Podoll & H.H. Friedemann. 1985. Longloop reflexes in small handmuscles studied in normal subjects and in patients with Huntington's disease. Brain 108(Pt 1): 65-80.
6. Abbruzzese, G. et al. 1990. Impaired habituation of long-latency stretch reflexes of the wrist muscles in Huntington's disease. Mov. Disord. 5: 32-35.
7. Blekher, T.M. et al. 2004. Oculomotor control in asymptomatic and recently diagnosed individuals with the genetic marker for Huntington's disease. Vision Res. 44: 2729-2736.
8. Lipper, S. 1973. Impairment of optokinetic nystagmus in patients with tardive dyskinesia. Arch. Gen. Psychiatry 28: 331-333.
9. Kirkwood, S.C. et al. 2000. Confirmation of subtle motor changes among presymptomatic carriers of the Huntington disease gene. Arch. Neurol. 57: 1040-1044.
10. Smith,M.A., J. Brandt & R. Shadmehr. 2000. Motor disorder in Huntington's disease begins as a dysfunction in error feedback control. Nature 403: 544-549.
11. Andrich, J. et al. 2007. Assessment of simple movements and progression of Huntington's disease. J. Neurol. Neurosurg. Psychiatry 78: 405-407. (Pubitemid 46580553)
12. Andrich, J. et al. 2007. Complexmovement behaviour and progression of Huntington's disease. Neurosci. Lett. 416: 272-274. (Pubitemid 46483870)
13. Paulsen, J.S. et al. 2008. Detection of Huntington's disease decades before diagnosis: The Predict-HD study. J. Neurol. Neurosurg. Psychiatry 79: 874-880.
14. 1996. Unified Huntington's Disease Rating Scale: Reliability and consistency. Huntington StudyGroup. Mov. Disord. 11: 136-142.
15. Martinez-Martin, P. et al. 1994. Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov. Disord. 9: 76-83.
16. Michell, A.W. et al. 2008. Hand tapping: A simple, reproducible, objective marker of motor dysfunction dysfunction in Huntington's disease. J. Neurol. 255: 1145-1152.
17. Blekher, T. et al. 2006. Saccades in presymptomatic and early stages of Huntington disease. Neurology 67: 394-399.
18. Peltsch, A. et al. 2008. Saccadic impairments inHuntington's disease. Exp. Brain Res. 186: 457-469.
19. Antoniades, C.A. et al. 2007. Saccadometry: A new tool for evaluating presymptomatic Huntington patients. Neuroreport 18: 1133-1136.
20. Henley, S.M., G.P. Bates & S.J. Tabrizi. 2005. Biomarkers for neurodegenerative diseases. Curr. Opin. Neurol. 18: 698-705.
21. Andrews, T.C. & D.J. Brooks. 1998. Advances in the understanding of early Huntington's disease using the functional imaging techniques of PET and SPET. Mol. Med. Today 4: 532-539.
22. Jernigan, T.L. et al. 1991. Cerebral structure onMRI, Part II: Specific changes in Alzheimer's and Huntington's diseases. Biol. Psychiatry 29: 68-81.
23. Kassubek, J. et al. 2004. Topography of cerebral atrophy in early Huntington's disease: A voxel based morphometric MRI study. J. Neurol. Neurosurg. Psychiatry 75: 213-220. (Pubitemid 38183526)
24. Rosas, H.D. et al. 2008. Cerebral cortex and the clinical expression of Huntington's disease: Complexity and heterogeneity. Brain 131: 1057-1068.
25. Ridha, B.H. et al. 2008. Volumetric MRI and cognitive measures in Alzheimer disease: Comparison of markers of progression. J. Neurol. 255: 567-574.
26. Wolf, R.C. et al. 2007. Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease: Evidence from event-related fMRI. Brain 130: 2845-2857.
27. Paulsen, J.S. et al. 2004. fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's disease. AJNR Am. J. Neuroradiol. 25: 1715-1721.
28. Reading, S.A. et al. 2004. Functional brain changes in presymptomatic Huntington's disease. Ann. Neurol. 55: 879-883.
29. Pavese, N. et al. 2003. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: A PET study. Brain 126: 1127-1135.
30. Leoni, V. et al. 2008. Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. Brain 131: 2851-2859.
31. Meier, A. et al. 2005. Normal hypocretin-1 (orexin- A) levels in the cerebrospinal fluid of patients with Huntington's disease. Brain Res. 1063: 201-203.
32. Dalrymple, A. et al. 2007. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J. Proteome Res. 6: 2833-2840.
33. Bjorkqvist, M. et al. 2008. A novel pathogenic pathway of immune activation detectable before clinical onsetinHuntington'sdisease. J.Exp.Med. 205: 1869-1877.